BEIJING – Freshly installed Commissioner Jiao Hong of the China National Drug Administration, formerly the CFDA, voiced the agency's plans to streamline review and approval of new drugs, encourage innovation, improve capacity to take a science-based approach, deepen industry's quality control efforts and step up monitoring of adverse events.